InvestSMART

CurveBeam AI Limited (ASX:CVB)

ALERT: Price-sensitive ASX Announcement for CVB
Current share price for CVB : $0.018 -0.061 (-77.22%)+
Announcement
Release
29 Jan 2026 9:13AM
Price at Release
$0.079
Full Release
download
Summary
CurveBeam AI Limited's Investor Webinar Presentation for Q2 FY26 highlighted significant commercial and regulatory advancements. The company secured purchase orders for five devices including HiRise™ and LineUp systems. A $4.0 million milestone investment was triggered through a commercialisation agreement with Shandong WeiYing, with efforts underway to facilitate regulatory engagement for HiRise™ in China. CurveBeam AI submitted an FDA 510(k) application for the BMD module, targeting clearance by mid-CY26. The company also advanced its HiRise™ robotic surgery system project and reported a cash balance, including pending funds, of A$8.03 million.
Key Points
  • CurveBeam AI received purchase orders for five devices in Q2 FY26.
  • A $4.0 million milestone investment was triggered and is pending final receipt.
  • Regulatory engagement for HiRise™ in China is advancing with WEGO Orthopaedics.
  • FDA 510(k) application submitted for BMD module, clearance targeted for mid-CY26.
  • HiRise™ project for robotic-aided surgical systems is progressing.
  • Cash balance reported at A$8.03 million including pending WEGO payment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.